NCT01399593View on ClinicalTrials.gov

Safety & Efficacy of Eculizumab to Prevent AMR in Living Donor Kidney Transplant Recipients Requiring Desensitization

PHASE2TerminatedINTERVENTIONAL
Enrollment

102

Participants

Timeline

Start Date

November 2, 2011

Primary Completion Date

May 13, 2014

Study Completion Date

November 13, 2015

Conditions
Antibody Mediated Rejection
Interventions
DRUG

Eculizumab

Trial Locations (41)

2050

Camperdown

3050

Parkville VIC

3168

Clayton VIC

5000

North Terrace

8036

Barcelona

10032

New York

20007

Washington D.C.

20162

Milan

21205

Baltimore

27599

Chapel Hill

30309

Atlanta

31059

Toulouse

35128

Padua

35294

Birmingham

37044

Tours

45267

Cincinnati

55905

Rochester

60612

Chicago

63110

St Louis

69120

Heidelberg

73112

Oklahoma City

75010

Paris

75743

Paris

77030

Houston

90095

Los Angeles

92037

La Jolla

94143

San Francisco

02115

Boston

07039

Livingston

01307

Dresden

3015 CE

Rotterdam

N-0027

Oslo

413 45

Gothenburg

SE 141 86

Huddinge

S 751 85

Uppsala

SE1 9RT

London

W12 0HS

London

OX3 7LJ

Oxford

B15 2TH

Birmingham

CB2 2QQ

Cambridge

CV2 2DX

Coventry

Sponsors
All Listed Sponsors
lead

Alexion Pharmaceuticals, Inc.

INDUSTRY